Study of SPG302 in Healthy Volunteers and ALS Participants

Phase 1 Completed 88 enrolled Spinogenix Novotech (Australia) Pty Limited · collab

RandomizedSequentialQuadruple-blindTreatment

Summary

The first-in-human Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SPG302 in healthy volunteers and ALS participants

Timeline

Start: 2023-07-03
Primary completion: 2025-06-27
Completion: 2025-06-27

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SPG302	Small molecule	—	Oral

Study of SPG302 in Healthy Volunteers and ALS Participants

Summary

Timeline

Drugs

Indications